Results 1 to 10 of about 5,732 (109)

Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study [PDF]

Scientific Reports
This study evaluates the effect of molnupiravir on clinical improvement, viral clearance and antibody responses of COVID-19 patients who previously developed immunity through vaccination or prior infection.
Serap Şimşek-Yavuz, Alpay Azap, Gülsüm Öztürk-Emiral, Hüsna Çevik, Rahmet Güner, Müge Ayhan, Belgin Coşkun, Aysun Benli, Yeşim Tok, Mustafa Önel, İlker İnanç-Balkan, Sezen Fansa, Fatma Zehra Güneşer, Mahir Kapmaz, Nilsun Altunal, Elif Selcen Beng, Özlem Aydın, Sezen Özge Özen, Seniha Başaran, Hasan Yağmur, Meryem Çalışkan, Melek-Nur Aslan, Neslihan Uyar, Burcu Atasoy Bozan, Mihriban Aksoy, Mehtap Aydın, Duygu Korkut Akyürek, Elif Mukime Sarıcaoğlu, Önder Ergönül, Sevim Meşe, Füsun Can, Mert Ahmet Kuşkucu, Ali Ağaçfidan, Filiz Pehlivanoğlu, Özlem Altuntaş-Aydın, Alper Gündüz   +35 more
doaj   +2 more sources

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Molecules, 2021
The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for COVID-19. Molnupiravir,
, Mandeep Kumar Arora
exaly   +3 more sources

Molnupiravir and Its Antiviral Activity Against COVID-19

Frontiers in Immunology, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden.
Huahao Fan, Xiaoping An, Lihua Song
exaly   +3 more sources

SARS-CoV-2 Error Catastrophe Under Molnupiravir: Mutagenic Enhancement Enables Viral Persistence with Impaired Fitness [PDF]

Viruses
Molnupiravir induces mutations that render severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-competent through error catastrophe mechanisms.
Yuriko Tomita, Kaya Miyazaki, Rika Mochizuki, Hideki Hasegawa   +3 more
doaj   +2 more sources

Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open‐Label, Fixed Sequence, Phase 1 Study [PDF]

Clinical and Translational Science
Molnupiravir is an orally administered prodrug of β‐D‐N4‐hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID‐19 in nonhospitalized adults at high risk of disease progression.
Jixiang Zhu, Danning Zhang, Zhiping Liu, Bei Yan, Yanqiao Zang, Weiwei Zhao, Fang Sun, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch, Haiyan Li   +10 more
doaj   +2 more sources

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Viruses, 2022
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses.
Zheng Yao Low, Vincent Chow, Sunil Lal
exaly   +3 more sources

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants

Metabolites, 2023
The nucleoside analog β-D-N4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19.
Lalitkumar K Vora, Vivek Chavda, Pankti Balar   +2 more
exaly   +3 more sources

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]

BMC Infectious Diseases
Background COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin, Shwu-Jiuan Lin, Yu-Hui Chang, Fu-Der Wang, Phung-Anh Nguyen, Phan Thanh Phuc, Whitney Burton, Nguyen Thi Kim Hien, Chia-Chieh Lin, Carlos Shu-Kei Lam, To-Chi Ha, Christine Y. Lu, Chih-Wei Huang, Hsuan-Chia Yang, Shiue-Ming Lin, Chieh Yang, Li-Hsuan Wang, Jason C. Hsu   +17 more
doaj   +2 more sources

Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells [PDF]

Pathogens
The cross-species spillover of coronaviruses is considered a serious public health risk. Feline coronavirus (FCoV), canine coronavirus (CCoV), and transmissible gastroenteritis virus (TGEV) are all classified under Alphacoronavirus suis and infect ...
Tomoyoshi Doki, Kazuki Shinohara, Kaito To, Tomomi Takano   +3 more
doaj   +2 more sources

Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice [PDF]

Journal of Virology
Bourbon virus (BRBV) is an emerging tick-borne virus that can cause severe and fatal disease in humans. BRBV is vectored via the Amblyomma americanum tick, which is widely distributed throughout the central, eastern, and southern United States ...
Gayan Bamunuarachchi, Fang R. Zhao, Traci L. Bricker, Kuljeet Seehra, Andrew Karp, Michael S. Diamond, Adrianus C. M. Boon   +6 more
doaj   +2 more sources